| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On November 2, 2026, Susan Podlogar gave notice of her resignation from service as a director of Tevogen Inc. (the “Company”), effective immediately. In connection with Ms. Podlogar’s resignation, the Company’s Board of Directors (the “B... |
| 03 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
THIS FIRST AMENDMENT TO LOAN AGREEMENT (this “Amendment”), dated as of October 27, 2026, between TEVOGEN INC. (formerly known as Tevogen Bio Holdings Inc.), a Delaware corporation, as borrower (“Borrower”) and The Patel Family, LLP, a De... |
| 30 Sep 2026 |
8-K: Other Events
Both previously disclosed Nasdaq compliance matters are now closed |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Tevogen Inc., a Delaware corporation (the “Company”), hereby grants shares of the Company’s common stock, par value $0.0001 per share (the “Stock”), to the Grantee named below, subject to the vesting conditions set forth below (such gran... |
| 10 Sep 2026 |
8-K: Other Events
On September 9, 2026, Tevogen Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had regained compliance with the $15 million minimum market value of publicly held share... |
| 26 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
THIS AMENDMENT NO. 2 (this “Amendment”) to the Tevogen Inc. 2024 Omnibus Incentive Plan (the “Plan”), which increases the number of shares available for issuance under the Plan by 100,000,000 shares, was adopted by the Board of Directors... |
| 30 Jul 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Section 1.1. Registered Office and Agent. The registered office of Tevogen Inc. (the “Corporation”) shall be as set forth in the Charter of the Corporation (the “Charter”). |
| 22 Apr 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On April 16, 2026, Tevogen Bio Holdings Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no longer meets Nasd... |
| 25 Mar 2026 |
8-K: Other Events
On March 20, 2026, Tevogen Bio Holdings Inc. (the “Company”) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requiremen... |
| 04 Mar 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of its common stock at a ratio of 50 for 1. Stockholders previou... |
| 25 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
THIS AMENDMENT NO. 1 (this “Amendment”) to the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (the “Plan”), which increases the number of shares available for issuance under the Plan by one hundred million (100,000,000) shares, wa... |
| 30 Jan 2026 |
8-K: Regulation FD Disclosure
WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shar... |
| 26 Sep 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On September 23, 2025, Tevogen Bio Holdings Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no longer meets ... |
| 10 Jul 2025 |
8-K: Other Events
As a result of restricted stock award grants approved by the Board of Directors of Tevogen Bio Holdings Inc. (the “Company”) on June 27, 2025, including a grant of 8,000,000 shares of restricted stock to the Company’s Chief Executive Off... |
| 03 Jul 2025 |
8-K: Entry into a Material Definitive Agreement
Tevogen Bio Holdings Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: |
| 30 Jun 2025 |
8-K: Other Events
On June 30, 2025, Ryan Saadi, founder and Chief Executive Officer of Tevogen Bio Holdings Inc. (the “Company”), provided the Company with a cash contribution of $500,000. The Company expects the contribution to be used to provide funding... |
| 23 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
The 2025 Annual Meeting of the Stockholders (the “Annual Meeting”) of Tevogen Bio Holdings Inc. (the “Company”) was held on June 23, 2025. As of April 30, 2025, the date of record for determining the stockholders entitled to vote on the ... |
| 03 Jun 2025 |
8-K: Entry into a Material Definitive Agreement
WHEREAS, Landlord and Tenant entered into that certain Lease Agreement, dated as of February 1, 2022 (the “Original Lease”), pursuant to which the Landlord leased to Tenant, and Tenant leased from Landlord, approximately 6,708 rentable s... |
| 25 Apr 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Section 1.1. Registered Office and Agent. The registered office of Tevogen Bio Holdings Inc. (the “Corporation”) shall be as set forth in the Charter of the Corporation (the “Charter”). |
| 17 Apr 2025 |
8-K: Regulation FD Disclosure
WARREN, N.J., Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced it has entered into an agreement with CD 8 Technology Services LLC (“CD8”) for the development and/or acquisition of a turn-key facility... |
Loading...